Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ASMB Relative to the S&P 500

ASMB Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Assembly Biosciences, Inc. (NASD:ASMB) seasonal charts above shows that a Buy Date of November 13 and a Sell Date of February 5 has resulted in a geometric average return of 4.81% above the benchmark rate of the S&P 500 Total Return Index over the past 14 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 14 years by an average of 32.74% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

To download ASMB seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ASMB